ImageneBio, Inc.
IMACIK 0001835579 · Biological Products, (No Diagnostic Substances) · Nasdaq
- Ikena Oncology, Inc. (until 2025-07-25)
Revenue (TTM)
$7.49M
−77.1% YoY
Q1 Apr 2026
Net Income (TTM)
−$49.06M
−24.0% YoY
Q1 Apr 2026
EPS Diluted (TTM)
−$7.72
+56.4% YoY
Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-713.3%
Q1 Apr 2026
Net Margin
-655.1%
Q1 Apr 2026
Free Cash Flow (TTM)
−$61.26M
Q1 Apr 2026
Cash
$76.05M
Q1 Apr 2026
Total Debt
$0
Q1 Apr 2026
Shares Outstanding
11.28M sh
Q1 Apr 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
Low Neutral
ImageneBio Restates 2025 Equity Plan with New Share Reserve
The company's amended stock option plan adds 850,000 newly approved shares to its total incentive pool.